Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
Cell Proliferation · 2023
DOI: 10.1111/cpr.13471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2023. Verfasst von Tian-Tian Ji und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Hauptthemen laut MEDLINE: Human Embryonic Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, Strategic Priority Research Program of Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Robust allogeneic immune reactions after transplantation impede the translational pace of human embryonic stem cells (hESCs)‐based therapies. Selective genetic editing of human leucocyte antigen (HLA) molecules has been proposed to generate hESCs with immunocompatibility, which, however, has not been specifically designed for the Chinese population yet. Herein, we explored the possibility of customizing immunocompatible hESCs based on Chinese HLA typing characteristics. We generated an immunocompatible hESC line by disrupting HLA‐B , HLA‐C , and CIITA genes while retaining HLA‐A*11:01 (HLA‐A*11:01‐retained, HLA‐A11 R ), which covers ~21% of the Chinese population. The immunocompatibility of HLA‐A11 R hESCs was verified by in vitro co‐culture and confirmed in humanized mice with established human immunity. Moreover, we precisely knocked an inducible caspase‐9 suicide cassette into HLA‐A11 R hESCs (iC9‐HLA‐A11 R ) to promote safety. Compared with wide‐type hESCs, HLA‐A11 R hESC‐derived endothelial cells elicited much weaker immune responses to human HLA‐A11 + T cells, while maintaining HLA‐I molecule‐mediated inhibitory signals to natural killer (NK) cells. Additionally, iC9‐HLA‐A11 R hESCs could be induced to undergo apoptosis efficiently by AP1903. Both cell lines displayed genomic integrity and low risks of off‐target effects. In conclusion, we customized a pilot immunocompatible hESC cell line based on Chinese HLA typing characteristics with safety insurance. This approach provides a basis for establishment of a universal HLA‐A R bank of hESCs covering broad populations worldwide and may speed up the clinical application of hESC‐based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
- National Stem Cell Resource Center, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
- Institute for Stem Cell and Regenerative Medicine, Chinese Academy of Sciences, Beijing, China.
- Key Laboratory of Organ Regeneration & Transplantation of Ministry of Education, The First Hospital of Jilin University, Jilin, China.
Förderung
- National Key Research and Development Program
- Strategic Priority Research Program of Chinese Academy of Sciences
- National Natural Science Foundation of China
- China Manned Space Program
- National Key Research and Development Program of China
Zitieren
APA
Ji, T. T., Niu, S. S., Fang, M. H., Xu, L. X., Wang, X., Zou, J., Xu, F., Zhang, M., Niu, R., Wu, J., Wang, L., Li, Z. K., Yang, Y. G., Hao, J., Li, W., Hu, Z., & Zhou, Q. (2023). Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies. Cell Proliferation. https://doi.org/10.1111/cpr.13471
Vancouver
Ji TT, Niu SS, Fang MH, Xu LX, Wang X, Zou J, et al. Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies. Cell Proliferation. 2023. doi:10.1111/cpr.13471
BibTeX
@article{Ji2023,
author = {Ji, Tian-Tian and Niu, Shuai-Shuai and Fang, Ming-Hui and Xu, Ling-Xue and Wang, Xin and Zou, Jun and Xu, Fei and Zhang, Meng and Niu, Rui and Wu, Jun and Wang, Lei and Li, Zhi-Kun and Yang, Yong-Guang and Hao, Jie and Li, Wei and Hu, Zheng and Zhou, Qi},
title = {Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies},
journal = {Cell Proliferation},
year = {2023},
doi = {10.1111/cpr.13471}
}
EUVIMED